8-K: Kineta Grants Exclusive Negotiation Rights to TuHURA Biosciences for VISTA Blocking Immunotherapy Program

Kineta has granted TuHURA Biosciences an exclusive right to negotiate the acquisition of its KVA12123 immunotherapy program, receiving a $5 million nonrefundable payment.

Summary

• Kineta, Inc. has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting TuHURA exclusive rights to negotiate the acquisition of Kineta's KVA12123 immunotherapy program.
• The exclusivity period runs until October 1, 2024, and may be extended by up to 20 days if negotiations are ongoing and TuHURA's merger with Kintara is not yet closed.
• TuHURA will pay Kineta a $5 million nonrefundable exclusivity payment, with $2.5 million paid on July 3, 2024, and the remaining $2.5 million due on July 15, 2024.
• An additional $150,000 payment is due for each 10-day extension of the exclusivity period, up to a maximum of $300,000.
• The exclusivity payment will be credited against any initial cash consideration in a potential definitive agreement between the companies.
• Kineta is obligated to continue the development of the KVA12123 program during the exclusivity period and provide TuHURA with access to information and personnel.
• Kineta must also cease all discussions with other parties regarding the sale or licensing of the KVA12123 program assets.
• TuHURA has the right to terminate negotiations at any time, in which case the exclusivity payment is considered fully paid to Kineta.

Sentiment

Score: 7

Explanation: The agreement is a positive development for Kineta, providing immediate cash and a potential path for the KVA12123 program. However, the deal is not yet finalized, and there are risks associated with the exclusivity period.

Positives

• Kineta receives a $5 million nonrefundable payment, providing immediate cash flow.
• The agreement provides a potential path for the further development and commercialization of KVA12123.
• TuHURA is a Phase 3 registration-stage immuno-oncology company, suggesting a strong partner for the program.
• The exclusivity payment will be credited against any initial cash consideration in a potential definitive agreement, increasing the potential value of the deal.
• The agreement allows Kineta to focus on other strategic alternatives while the exclusivity period is in effect.

Negatives

• The agreement does not guarantee a definitive acquisition of the KVA12123 program by TuHURA.
• Kineta is restricted from engaging with other potential partners during the exclusivity period.
• If TuHURA terminates negotiations, Kineta will have to seek other options for the program.
• The agreement requires Kineta to continue the development of the KVA12123 program during the exclusivity period, which may incur additional costs.

Risks

• There is a risk that TuHURA may not proceed with a definitive agreement to acquire the KVA12123 program.
• The exclusivity period may expire without a deal, leaving Kineta to find another partner.
• Kineta may incur costs associated with maintaining the program during the exclusivity period without a guaranteed return.
• The agreement could potentially limit Kineta's ability to explore other strategic alternatives during the exclusivity period.
• There is a risk that the potential transaction may not be completed on attractive terms for Kineta.

Future Outlook

Kineta is exploring strategic alternatives to maximize stockholder value, with this agreement being a potential step in that direction. The company anticipates additional data from the KVA12123 clinical trial in the fourth quarter of 2024.

Management Comments

• TuHURA Biosciences is well positioned to advance KVA12123, said Craig W. Philips, President of Kineta.
• We believe they will make an excellent partner for this program and in advancing this novel drug program which could provide an important new treatment option for cancer patients.

Industry Context

This agreement reflects the ongoing trend of consolidation and strategic partnerships in the biotechnology industry, particularly in the immuno-oncology space. Companies are increasingly seeking to leverage each other's assets and expertise to accelerate drug development and commercialization.

Comparison to Industry Standards

• The exclusivity agreement is a common practice in the biotech industry when considering potential acquisitions or licensing deals.
• The $5 million upfront payment is a significant amount for an exclusivity agreement, suggesting a strong interest from TuHURA in the KVA12123 program.
• The potential for additional payments based on extensions is also a standard practice to compensate for the time and resources spent during due diligence.
• Compared to other similar deals, the terms of this agreement appear to be favorable for Kineta, given the nonrefundable nature of the payment and the potential for further consideration.

Stakeholder Impact

• Shareholders may view this agreement positively as it provides a potential path for the KVA12123 program and immediate cash.
• Employees may be impacted by the potential acquisition of the program, but the agreement does not specify any immediate changes.
• Customers and suppliers are not directly impacted by this agreement.
• Creditors may view this agreement positively as it improves Kineta's financial position.

Next Steps

• TuHURA will conduct due diligence on the KVA12123 program.
• Kineta and TuHURA will negotiate the terms of a potential definitive agreement.
• Additional data from the KVA12123 clinical trial is expected in the fourth quarter of 2024.

Key Dates

Keywords

KVA12123, immunotherapy, VISTA blocking antibody, TuHURA Biosciences, exclusivity agreement, acquisition, oncology, clinical trial, biotechnology, strategic transaction